Jubilant Pharmova Limited announced its unaudited financial results for the quarter and nine months ended December 31, 2025. The Board of Directors approved these results during a meeting held on February 6, 2026. The company reported standalone revenue from operations of ₹673 crore for the quarter ended December 31, 2025, compared to ₹561 crore in the same period last year. For the nine months ended December 31, 2025, standalone revenue was ₹1,931 crore. The standalone profit before tax for the quarter was ₹101 crore, and for the nine months, it was ₹251 crore. On a consolidated basis, the company reported total revenue from operations of ₹21,225 crore for the quarter ended December 31, 2025, and ₹59,896 crore for the nine months ended December 31, 2025. Consolidated profit before tax for the quarter stood at ₹934 crore, and for the nine months, it was ₹4,381 crore. The results also include details on discontinued operations related to the sale of the Active Pharmaceutical Ingredients (API) business to Jubilant Biosys Limited, which was completed on September 1, 2025. The company has reclassified this business as discontinued operations for all periods presented. The financial results have been subjected to a limited review by the statutory auditors, Walker Chandiok & Co LLP. The detailed financial results are available on the company's website and stock exchange filings.
